Press Releases

Bioengineered Organ Implant Company HART to Present at RegMed Capital Conference in Atlanta, Friday Dec. 11 at 9:00 am ET

ATLANTA and HOLLISTON, Mass., Dec. 3, 2015 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the RegMed Capital Conference on Friday, December 11, 2015 at 9:00 a.m. ET.. The conference will be held at the Hyatt Regency in Atlanta, GA co-located with the World Stem Cell Summit.

HART logo

HART CEO, Jim McGorry will review the company's business strategy and opportunities and comment on HART's recent animal studies that revealed significant results from its second generation (Gen2) bioengineered esophageal, tracheal and bronchial implants, as well as the company's near-term milestones. HART has initiated confirmatory large-animal studies of its Gen2 implants in collaboration with Mayo Clinic.  The study design has been completed, prerequisite tests are underway and the Company expects the animal surgeries to occur in December. HART looks to initiate human compassionate use procedures during 2016.  Also, the Company plans to file an IND application with the U.S. FDA in 2016, seeking to commence clinical trials for one of HART's three product candidates.

About RegMed Capital Conference (www.regmed-capital-conference)

Spurred by the unprecedented convergence of 21st Century technologies, the RegMed Capital Conference provides attendees with the critical information needed to understand the unlimited potential of regenerative medicine, immunotherapy, cell therapies and related industries. The conference, a co-located meeting at the World Stem Cell Summit (, is committed to advancing commercialization and investment opportunities for biotech companies.

About HART: (

Harvard Apparatus Regenerative Technology (HART) makes bioengineered organ implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the airways (trachea and bronchus). HART is completing further large-animal studies to refine our technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates. Our first-generation trachea technology was used in five adult human trachea transplants approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any HART products by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of HART products, including those pertaining to the airway or esophagus, which such success may not be achieved or obtained on a timely basis or at all . These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for the our implant products, bioreactors, scaffolds and other devices and product candidates we pursue; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Twitter:  Investor Relations @HART_IR_Team 
StockTwits: @HART_IR

Catalyst Global LLC 
David Collins, Tanya Kamatu 

Logo -

SOURCE Harvard Apparatus Regenerative Technology, Inc.